CN105362885A - Medicine composition for treating gastric mucosa intestinal metaplasia - Google Patents
Medicine composition for treating gastric mucosa intestinal metaplasia Download PDFInfo
- Publication number
- CN105362885A CN105362885A CN201510852900.3A CN201510852900A CN105362885A CN 105362885 A CN105362885 A CN 105362885A CN 201510852900 A CN201510852900 A CN 201510852900A CN 105362885 A CN105362885 A CN 105362885A
- Authority
- CN
- China
- Prior art keywords
- parts
- gastric mucosa
- intestinal metaplasia
- rhizoma
- roth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine composition for treating gastric mucosa intestinal metaplasia. The medicine composition is prepared from, by weight, 11-20 parts of enteromorpha clathrata, 18-26 parts of hylocereus undatus, 10-17 parts of caulis perllae, 5-9 parts of rhizoma corydalis, 18-26 parts of salvia chinensis, 18-26 parts of primula malacoides, 3-6 parts of rhizoma alpiniae officinarum, 3-6 parts of rhizoma nardostachyos and 5-9 parts of hyacinth dolichos seed-coat. The medicine composition is capable of blocking and reversing gland metaplasia and a cancerization process by adjusting body immune function, improving local blood circulation, enhancing protection of gastric mucosa and recovering balance between aggressive factors and defensive factors, and suitable for being used to treat the gastric mucosa intestinal metaplasia.
Description
Technical field
The present invention relates to a kind of Chinese medicinal formulae, particularly relate to a kind of pharmaceutical composition for the treatment of intestinal metaplasia of gastric mucosa and preparation method thereof, belong to technical field of Chinese medicines.
Background technology
The intestinal epithelial metaplasia (intestinalmetaplasia, IM) of gastric mucosa is called when there is visible peristalsis visible intestinal peristalsis epithelium in gastric mucosa.Correa proposes emergence pattern i.e. " normal gastric mucosa-superficial gastritis-atrophic gastritis-intestinal epithelial metaplasia-atypical hyperplasia-gastric cancer " (CorreaP.Humangastriccarcinogenesis:amultistepandmultifac torialprocess-FirstAmericanCancerSocietyAwardLectureonCa ncerEpidemiologyandPrevention [J] .CancerRes of gastric cancer, 1992,52:6735-6740.).Guan Renzhen etc. carry out retrospective study to 183960 customary Endoscopic patients, total recall rate of IM is 3.86%, the continuous scope patient of part IM being reached to 9 years is followed up a case by regular visits to, canceration recall rate is 4.26% ~ 9.09% (Guan Renzhen, Liu Wentian, Wang Bangmao, etc. the appreciation of endoscope [J] of Gastric mucosal dysplasia and intestinalization life. gastroenterology and hepatopathy magazine, 2008,17 (2): 136-138.).Epidemiological study also confirms, gastric intestinal metaplasia has high carcinogenic risk (Li Kai, Tang Zhipeng, Zheng Fengjie, Deng. the Reversibility problem [J] of intestinal metaplasia in chronic gastritis. world Chinese digests magazine, and 2007,15 (2): 140-144.).Therefore, study and develop a kind of medicine for the treatment of intestinal metaplasia of gastric mucosa, this seems particularly urgent.
Summary of the invention
In view of the high carcinogenic risk that the intestinal epithelial metaplasia of gastric mucosa exists, the object of the present invention is to provide a kind of pharmaceutical composition for the treatment of intestinal metaplasia of gastric mucosa.
In order to realize object of the present invention, inventor is also constantly explored by lot of experiments research, finally obtains following technical scheme:
Treat a pharmaceutical composition for intestinal metaplasia of gastric mucosa, it is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Enteromorpha clathrata (Roth) Grev. Emend bliding 11-20 part, Hylocereus undatus 18-26 part, Caulis Perillae 10-17 part, Rhizoma Corydalis 5-9 part, Herba Salviae Chinensis 18-26 part, Flos Primulae Vittatae 18-26 part, Rhizoma Alpiniae Officinarum 3-6 part, Radix Et Rhizoma Nardostachyos 3-6 part, Testa dolichoris 5-9 part.
Preferably, the pharmaceutical composition for the treatment of intestinal metaplasia of gastric mucosa described above, it is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Enteromorpha clathrata (Roth) Grev. Emend bliding 14-16 part, Hylocereus undatus 21-23 part, Caulis Perillae 12-14 part, Rhizoma Corydalis 6-8 part, Herba Salviae Chinensis 21-23 part, Flos Primulae Vittatae 21-23 part, Rhizoma Alpiniae Officinarum 4-6 part, Radix Et Rhizoma Nardostachyos 4-6 part, Testa dolichoris 6-8 part.
In a most preferred embodiment of the present invention, the pharmaceutical composition for the treatment of intestinal metaplasia of gastric mucosa described above, it is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Enteromorpha clathrata (Roth) Grev. Emend bliding 15 parts, Hylocereus undatus 22 parts, Caulis Perillae 13 parts, Rhizoma Corydalis 7 parts, Herba Salviae Chinensis 22 parts, Flos Primulae Vittatae 22 parts, Rhizoma Alpiniae Officinarum 5 parts, Radix Et Rhizoma Nardostachyos 5 parts, Testa dolichoris 7 parts.
It should be noted that, pharmaceutical composition of the present invention adopt in preparation process traditional Chinese medicinal material raw materials source as follows: Enteromorpha clathrata (Roth) Grev. Emend bliding selects the frond of Ulvaceae plant Enteromorpha clathrata (Roth) Greville Enteromorphaclathrata (Roth) Grev.; The dry meat stem of Cactaceae Hylocereus undatus platymiscium Hylocereus undatus Hylocereusundatus (Haw.) Britt.etRose selected by Hylocereus undatus; Caulis Perillae selects the dry stem of labiate Folium Perillae Perillafrutescens (L.) Britt.; Rhizoma Corydalis selects the dry tuber of papaveraceae plant corydalis CorydalisyanhusuoW.T.Wang; Herba Salviae Chinensis selects the dry herb of Lamiaceae Salvia platymiscium Herba Salviae Chinensis SaIviachinensiaBenth.; Flos Primulae Vittatae select the dry herb of Ofthe Primulaceae Flos Primulae Vittatae PrimulamalacoidesFranch.; The dry rhizome of zingiberaceous plant Rhizoma Alpiniae Officinarum AlpiniaofficinarumHance selected by Rhizoma Alpiniae Officinarum; The dry root and rhizome of Valerianaceae plant Radix Et Rhizoma Nardostachyos NardostachyschinensisBatal. selected by Radix Et Rhizoma Nardostachyos; Testa dolichoris selects the dry seed coat of leguminous plant Seem Lablab Album DolichoslablabL..
Compared with prior art; pharmaceutical composition provided by the present invention can improve the clinical symptoms (comprising stomach painful abdominal mass, flatulence, stomachache, pantothenic acid, belch, hungry noise, weak and poor appetite) of intestinal metaplasia of gastric mucosa patient; by conditioner body immunity function; improve local blood circulation; strengthen the protection of gastric mucosa; the balance of resuming the attack between the factor and defense factor; thus block and reverse the process of body of glandization life and canceration; this medicine is without obvious adverse reaction simultaneously, is applicable to treatment intestinal metaplasia of gastric mucosa.
Detailed description of the invention
Be below preparation embodiment and the clinical practice example of pharmaceutical composition of the present invention, technical scheme of the present invention and technique effect done and describes and explain further.
Embodiment 1: the preparation of Chinese medicine oral liquid
Take Enteromorpha clathrata (Roth) Grev. Emend bliding 1.5kg, Hylocereus undatus 2.2kg, Caulis Perillae 1.3kg, Rhizoma Corydalis 0.7kg, Herba Salviae Chinensis 2.2kg, Flos Primulae Vittatae 2.2kg, Rhizoma Alpiniae Officinarum 0.5kg, Radix Et Rhizoma Nardostachyos 0.5kg and Testa dolichoris 0.7kg, mixing, put during multi-functional extraction is filled with and decoct with water twice, add up the water of medical material 12 times amount for the first time, boil rear slow fire boiling 2h, get decocting liquid, filter, second time adds up the water of medical material 10 times amount, boil rear slow fire boiling 1.5h, get twice decocting liquid to merge, filter, be concentrated into every milliliter containing 1.1g crude drug amount, put 2-5 DEG C of deepfreeze 24h, cold preservation liquid is filtered, the antiseptic adding 0.1% stirs evenly, fill, obtain Chinese medicine oral liquid.
Embodiment 2: the experimental study for the treatment of by Chinese herbs intestinal metaplasia of gastric mucosa
Intestinal metaplasia of gastric mucosa patient 86 example made a definite diagnosis after endoscopy and the inspection of gastric mucosa biopsy histology, wherein man 37 example, female 49 example, age 39-71 year, the mean age (53.6 ± 6.0) year, intestinal metaplasia of gastric mucosa pathological grading: slight 54 example, moderate 21 example, severe 11 example.Selected patient is divided at random test group 43 example and matched group 43 example.In the raw pathological grade formation of sex, age and Gastric Mucous Membrane with Intestinal Metaplasia, there is no significant difference before two groups of patient treatments, there is comparability.Test group patient takes Chinese medicinal formulae of the present invention treatment, and prescription consists of: Enteromorpha clathrata (Roth) Grev. Emend bliding 15g, Hylocereus undatus 22g, Caulis Perillae 13g, Rhizoma Corydalis 7g, Herba Salviae Chinensis 22g, Flos Primulae Vittatae 22g, Rhizoma Alpiniae Officinarum 5g, Radix Et Rhizoma Nardostachyos 5g, Testa dolichoris 7g; Decocting potion, morning and evening every day decoction being taken warmly after meal.Matched group gives Pantoprazole Sodium Enteric-Coated Capsules (Zhongmei Huadong Pharmaceutical Co., Ltd. Hangzhou, the accurate word H20010032 of traditional Chinese medicines), each 40mg, every day early decoction being taken at a draught before the meal; Hydrotalcite tablet (Bayer HealthCare Co, the accurate word H20013410 of traditional Chinese medicines), each 1g, every day 3 times.Total course for the treatment of of two groups is 3 months.
Two groups all before the treatment after be responsible for gastroscopy by special messenger, conventional get 2 pieces and 1 piece of specimen respectively in gastric antrum stomach function regulating angle, want another label taking originally to the focus that may or certainly exist.Specimen is sufficiently large, reaches muscularis mucosae, and takes pictures to before and after diseased region treatment., follow the principle of " who finds, whose further consultation " meanwhile, after transferring gastroscope record last time, get biopsy at identical or close position as far as possible.Pathologic specimen formalin is fixed, and paraffin-embedded tissue is cut into slices, and carries out HE and immunohistochemical staining respectively." Chinese National Consensus on Chronic Gastritis " (Chinese Medical Association's disease for digest credit meeting. Chinese National Consensus on Chronic Gastritis [J]. gastroenterology, 2006,11 (11): 674-679.) intestinal metaplasia of gastric mucosa is divided into without, slight, moderate, severe level Four carry out mark (0-3 divides) respectively, observes the situation of change of intestinal metaplasia of gastric mucosa before and after treatment as criterion.The long-pending 0 point of person of scope check is recovery from illness, and integration reduces by 2 points of persons for effective, and it is effective that integration reduces by 1 point of person, and the unchanged person of integration or enhancer are invalid.
Before and after two groups of patient treatments, biological tissue intestinal metaplasia of gastric mucosa degree comparative result is in table 1.Before treatment, the intestinal metaplasia of gastric mucosa pathological examination of two groups of patients compares no significant difference.After treatment, the situation of two groups of patient's intestinal metaplasia of gastric mucosa is all significantly improved, and test group comparatively matched group improve more obvious.
Before and after table 1 liang group patient treatment, biological tissue intestinal metaplasia of gastric mucosa degree compares
Before and after two groups of patient treatments, biological tissue intestinal metaplasia of gastric mucosa comparitive study the results are shown in Table 2.After treatment, the effective percentage that matched group patient intestinal metaplasia of gastric mucosa improves is 27.9%, and test group is 81.4%, and the curative effect of obvious test group is better than matched group.
Biological tissue intestinal metaplasia of gastric mucosa comparitive study before and after table 2 liang group patient treatment
Treatment is omnidistance to be observed, the untoward reaction that record patient occurs.Observed result shows, and matched group has that diarrhoea appears in 1 example, headache appears in 1 example, erythra appears in 1 example, and 3 examples all do not affect continual cure, and untoward reaction is died away in treatment or after terminating; For there is untoward reaction case in test group.
Above-mentioned is can understand and apply the invention for ease of those skilled in the art to the description of embodiment.Person skilled in the art obviously easily can make various amendment to these embodiments, and General Principle described herein is applied in other embodiments and need not through performing creative labour.Therefore, the invention is not restricted to embodiment here, those skilled in the art, according to announcement of the present invention, do not depart from improvement that scope makes and amendment all should within protection scope of the present invention.
Claims (5)
1. treat the pharmaceutical composition of intestinal metaplasia of gastric mucosa for one kind, it is characterized in that, it is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Enteromorpha clathrata (Roth) Grev. Emend bliding 11-20 part, Hylocereus undatus 18-26 part, Caulis Perillae 10-17 part, Rhizoma Corydalis 5-9 part, Herba Salviae Chinensis 18-26 part, Flos Primulae Vittatae 18-26 part, Rhizoma Alpiniae Officinarum 3-6 part, Radix Et Rhizoma Nardostachyos 3-6 part, Testa dolichoris 5-9 part.
2. treat the pharmaceutical composition of intestinal metaplasia of gastric mucosa according to claim 1, it is characterized in that, it is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Enteromorpha clathrata (Roth) Grev. Emend bliding 14-16 part, Hylocereus undatus 21-23 part, Caulis Perillae 12-14 part, Rhizoma Corydalis 6-8 part, Herba Salviae Chinensis 21-23 part, Flos Primulae Vittatae 21-23 part, Rhizoma Alpiniae Officinarum 4-6 part, Radix Et Rhizoma Nardostachyos 4-6 part, Testa dolichoris 6-8 part.
3. treat the pharmaceutical composition of intestinal metaplasia of gastric mucosa according to claim 2, it is characterized in that, it is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Enteromorpha clathrata (Roth) Grev. Emend bliding 15 parts, Hylocereus undatus 22 parts, Caulis Perillae 13 parts, Rhizoma Corydalis 7 parts, Herba Salviae Chinensis 22 parts, Flos Primulae Vittatae 22 parts, Rhizoma Alpiniae Officinarum 5 parts, Radix Et Rhizoma Nardostachyos 5 parts, Testa dolichoris 7 parts.
4. according to any one of claim 1-3, treat the pharmaceutical composition of intestinal metaplasia of gastric mucosa, it is characterized in that, described Enteromorpha clathrata (Roth) Grev. Emend bliding is the frond of Ulvaceae plant Enteromorpha clathrata (Roth) Greville Enteromorphaclathrata (Roth) Grev..
5. the application of the traditional Chinese medicinal material raw materials compositions described in any one of claim 1-3 in the medicine of preparation treatment intestinal metaplasia of gastric mucosa.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510852900.3A CN105362885A (en) | 2015-11-27 | 2015-11-27 | Medicine composition for treating gastric mucosa intestinal metaplasia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510852900.3A CN105362885A (en) | 2015-11-27 | 2015-11-27 | Medicine composition for treating gastric mucosa intestinal metaplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105362885A true CN105362885A (en) | 2016-03-02 |
Family
ID=55365837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510852900.3A Withdrawn CN105362885A (en) | 2015-11-27 | 2015-11-27 | Medicine composition for treating gastric mucosa intestinal metaplasia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105362885A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102671104A (en) * | 2012-06-01 | 2012-09-19 | 康厚彬 | Stomach medicine |
| CN103463579A (en) * | 2013-09-27 | 2013-12-25 | 大连华慈生物科技开发有限公司 | Traditional Chinese medicine for treating stomach diseases and preparation method thereof |
-
2015
- 2015-11-27 CN CN201510852900.3A patent/CN105362885A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102671104A (en) * | 2012-06-01 | 2012-09-19 | 康厚彬 | Stomach medicine |
| CN103463579A (en) * | 2013-09-27 | 2013-12-25 | 大连华慈生物科技开发有限公司 | Traditional Chinese medicine for treating stomach diseases and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 吴林鹏: "香苏和胃饮治疗慢性浅表性胃炎100例", 《河北中医》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008650B (en) | Compound traditional Chinese medicine preparation for treating tumors and preparation method thereof | |
| CN102451268B (en) | Traditional Chinese medicine preparation for treating helicobacter pylori related gastropathy and preparation method | |
| CN111870681B (en) | Traditional Chinese medicine composition for treating asthma and application thereof | |
| CN108272961A (en) | A kind of Chinese medicine composition that treating stomach trouble and preparation method and its application in terms of stomach invigorating | |
| CN111840456A (en) | Chinese medicinal composition for treating respiratory system diseases | |
| CN106390065A (en) | Application of traditional Chinese medicine preparation in treating and/or preventing laryngo-pharyngeal reflux | |
| CN103182059A (en) | Traditional Chinese medicine composition for treating chronic gastritis, and application thereof | |
| CN103356880B (en) | Chinese patent medicine for promoting gastrointestinal motility and its preparation method | |
| CN105362885A (en) | Medicine composition for treating gastric mucosa intestinal metaplasia | |
| CN114788858A (en) | Traditional Chinese medicine pill for treating nodules as well as preparation method and application thereof | |
| CN103908581A (en) | Drug for treating bladder cancer and preparation method thereof | |
| CN104000938B (en) | Traditional Chinese medicine composition for treating IgA nephropathy and application thereof | |
| CN107029084A (en) | A kind of Chinese medicine composition and its pharmaceutical preparation for treating Colon and rectum precancerous lesion and application | |
| CN104116956A (en) | Pharmaceutical composition for treating cancer pain in anesthesia department | |
| CN104096053A (en) | Medicine composition for treating infantile pneumonia | |
| CN103877557B (en) | A kind of Chinese medicine ointment and preparation method for the treatment of tinea unguium | |
| CN101693096A (en) | Medicament for treating liver cancer and preparation method thereof | |
| CN105596590A (en) | Traditional Chinese medicine preparation for treating herpes labialis and preparation method thereof | |
| CN104606377A (en) | Traditional Chinese medicinal composition for treating gastritis | |
| CN105853653A (en) | Pharmaceutical composition for treating digestive system disease and preparation method thereof | |
| CN105535799A (en) | Medicine for treating chronic cholecystitis and preparation method | |
| CN103908566A (en) | A traditional Chinese medicine medicament used for treating chronic atrophic gastritis and a preparing method thereof | |
| CN103735820B (en) | A kind ofly treat the pharmaceutical composition that pulmonary abscess and lung qi are breathed heavily | |
| CN105106509A (en) | Traditional Chinese medicine oral liquid for treating oral leukoplakia | |
| CN104984187A (en) | Traditional Chinese medicine used for treating chronic gastritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160302 |